Developer docs
API playgroundTry for free, no card

Search company profiles

NodThera

Full company profile

uuid0000k2d

Namestring
NodThera
Legal namestring
NodThera
Websiteurl
nodthera.com
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLittle Chesterford, United Kingdom
HQ citystring
Little Chesterford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
NLRP3 inflammasome inhibitors, cardiometabolic disease therapeutics, neuroinflammatory disease drugs, small molecule drug discovery, anti-inflammatory therapeutics
Industry2 codes
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Inflammatory Disease Therapeutics
Social media profiles2 records
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NodThera is a clinical-stage biotechnology company developing a portfolio of brain-penetrant, oral small-molecule NLRP3 inflammasome inhibitors designed to treat chronic cardiometabolic and neuroinflammatory diseases. The company's pipeline includes three clinical-stage drug candidates: Ruvonoflast (NT-0796) as the lead molecule for cardiometabolic diseases currently in Phase 2 trials, NT-0150 as a next-generation brain-penetrant inhibitor for neuroinflammatory diseases in Phase 1, and NT-0249 as a CSF-penetrant Phase 2-ready candidate.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Ruvonoflast lowered hsCRP by 82% in patients at high risk of ASCVD
+5 more records
Product overview1 text field

NodThera is a clinical-stage biotech company developing a portfolio of brain-penetrant oral small-molecule NLRP3 inhibitors to treat cardiometabolic and neuroinflammatory diseases. The company's pipeline consists of three clinical-stage programs: Ruvonoflast (NT-0796) as the lead candidate for cardiometabolic diseases currently in Phase 2; NT-0150 as a next-generation brain-penetrant inhibitor for neuroinflammatory diseases in Phase 1; and NT-0249 as a CSF-penetrant inhibitor for chronic inflammatory diseases that is Phase 2-ready. All candidates target the NLRP3 inflammasome to address upstream inflammation drivers while preserving immune defense capability.

Product and service3 records
1Ruvonoflast (NT-0796)
CategoryCardiometabolic Disease Therapeutics
Description

Lead molecule and brain-penetrant oral NLRP3 inhibitor designed to reduce persistent inflammation driving cardiometabolic diseases. Currently in two Phase 2 clinical trials (RESOLVE-1 and RESOLVE-2) for cardiometabolic diseases. Targets patients with atherosclerotic cardiovascular disease (ASCVD) with residual inflammatory risk. Demonstrated 82% reduction in hsCRP in clinical studies.

2NT-0150
CategoryNeuroinflammatory Disease Therapeutics
Description

Next-generation brain-penetrant NLRP3 inhibitor being developed for neuroinflammatory diseases. Phase 1 clinical studies are underway. Demonstrated excellent preclinical efficacy reducing central and peripheral inflammatory markers across multiple animal models.

3NT-0249
CategoryInflammatory Disease Therapeutics
Description

Potent NLRP3 inhibitor with excellent cerebrospinal fluid (CSF) penetration optimized for chronic inflammatory diseases of the body. Currently Phase 2-ready.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct NLRP3 inflammasome inhibitor peer developing dapansutrile in cardiometabolic and inflammatory indications. Closely comparable mechanism, target indications, and clinical-stage positioning to NodThera.

2Inflazome (Roche)
TypeDirect peer
Description

NLRP3 inhibitor developer acquired by Roche in 2020; one of NodThera's most direct competitors and a comparable oral small-molecule NLRP3 play, now with Roche's resources.

TypeDirect peer
Description

NLRP3 antagonist program originally developed by IFM Tre and acquired by Novartis. Directly comparable mechanism and inflammatory-disease focus, now backed by large-pharma resources.

TypeEmerging player
Description

India-based pharma with internal NLRP3 inflammasome inhibitor programs in cardiometabolic indications; comparable mechanism, partial geographic overlap.

5Bristol Myers Squibb (NLRP3 via IFM)
TypeBroad incumbent
Description

Big pharma that had NLRP3 programs via the IFM Due (originally with BMS) and broader inflammation pipeline; comparable therapeutic area with vastly greater scale.

TypeBroad incumbent
Description

Investor in NodThera and developer of semaglutide; overlapping cardiometabolic/obesity franchise where NodThera's anti-inflammatory approach could be complementary or competitive.

TypeBroad incumbent
Description

Major player in cardiometabolic disease with the Farxiga (dapagliflozin) franchise and an obesity franchise led by ex-NodThera board member Elisabeth Björk; overlapping therapeutic area and large commercial scale.

TypeBroad incumbent
Description

Major inflammation and cardiometabolic player (Repatha, Otezla); comparable therapeutic area where NodThera's CMO Jyothis George previously led obesity medical affairs.

TypeEmerging player
Description

Clinical-stage biotech developing novel small-molecule immunology/inflammation therapies (including IRAK4 degrader); Don Nicholson (NodThera's chairman) is also on Kymera's board. Comparable clinical-stage inflammation focus.

TypeEmerging player
Description

Clinical-stage biotech founded by NodThera's CSO Alan Watt (as acting CSO). Comparable clinical-stage size and inflammation/oncology therapeutic area positioning.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NodThera

Inflammatory Disease Therapeuticsnodthera.com

NodThera firmographics

Firmographics
Name
NodThera
Legal name
NodThera
Website
https://nodthera.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

NodThera industry classification

Industry
Product category
Inflammatory Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • NLRP3 inflammasome inhibitors
  • Cardiometabolic disease therapeutics
  • Neuroinflammatory disease drugs
  • Small molecule drug discovery
  • Anti-inflammatory therapeutics

Where NodThera is headquartered

Location

Headquarters

HQ city
Little Chesterford
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

NodThera business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Marketing channels5 records

NodThera product offering

Product offering

Core offering

NodThera is a clinical-stage biotechnology company developing a portfolio of brain-penetrant, oral small-molecule NLRP3 inflammasome inhibitors designed to treat chronic cardiometabolic and neuroinflammatory diseases. The company's pipeline includes three clinical-stage drug candidates: Ruvonoflast (NT-0796) as the lead molecule for cardiometabolic diseases currently in Phase 2 trials, NT-0150 as a next-generation brain-penetrant inhibitor for neuroinflammatory diseases in Phase 1, and NT-0249 as a CSF-penetrant Phase 2-ready candidate.

Product overview

NodThera is a clinical-stage biotech company developing a portfolio of brain-penetrant oral small-molecule NLRP3 inhibitors to treat cardiometabolic and neuroinflammatory diseases. The company's pipeline consists of three clinical-stage programs: Ruvonoflast (NT-0796) as the lead candidate for cardiometabolic diseases currently in Phase 2; NT-0150 as a next-generation brain-penetrant inhibitor for neuroinflammatory diseases in Phase 1; and NT-0249 as a CSF-penetrant inhibitor for chronic inflammatory diseases that is Phase 2-ready. All candidates target the NLRP3 inflammasome to address upstream inflammation drivers while preserving immune defense capability.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ruvonoflast (NT-0796) Lead molecule and brain-penetrant oral NLRP3 inhibitor designed to reduce persistent inflammation driving cardiometabolic diseases. Currently in two Phase 2 clinical trials (RESOLVE-1 and RESOLVE-2) for cardiometabolic diseases. Targets patients with atherosclerotic cardiovascular disease (ASCVD) with residual inflammatory risk. Demonstrated 82% reduction in hsCRP in clinical studies.
  • NT-0150 Next-generation brain-penetrant NLRP3 inhibitor being developed for neuroinflammatory diseases. Phase 1 clinical studies are underway. Demonstrated excellent preclinical efficacy reducing central and peripheral inflammatory markers across multiple animal models.
  • NT-0249 Potent NLRP3 inhibitor with excellent cerebrospinal fluid (CSF) penetration optimized for chronic inflammatory diseases of the body. Currently Phase 2-ready.

Quantifiable outcome

  • Ruvonoflast lowered hsCRP by 82% in patients at high risk of ASCVD
  • +5 more outcomes

Companies that use NodThera

Customer profile

Segments3 records

Ideal customer profiles1 record

NodThera technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

NodThera partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights5 records

NodThera competitors and assessment

Company assessment

Direct peers

  • Olatec Therapeutics: Direct NLRP3 inflammasome inhibitor peer developing dapansutrile in cardiometabolic and inflammatory indications. Closely comparable mechanism, target indications, and clinical-stage positioning to NodThera.
  • Inflazome (Roche): NLRP3 inhibitor developer acquired by Roche in 2020; one of NodThera's most direct competitors and a comparable oral small-molecule NLRP3 play, now with Roche's resources.
  • IFM Tre (Novartis): NLRP3 antagonist program originally developed by IFM Tre and acquired by Novartis. Directly comparable mechanism and inflammatory-disease focus, now backed by large-pharma resources.

Emerging players

  • Zydus Cadila (NLRP3 programs): India-based pharma with internal NLRP3 inflammasome inhibitor programs in cardiometabolic indications; comparable mechanism, partial geographic overlap.
  • Kymera Therapeutics: Clinical-stage biotech developing novel small-molecule immunology/inflammation therapies (including IRAK4 degrader); Don Nicholson (NodThera's chairman) is also on Kymera's board. Comparable clinical-stage inflammation focus.
  • Bicycle Therapeutics: Clinical-stage biotech founded by NodThera's CSO Alan Watt (as acting CSO). Comparable clinical-stage size and inflammation/oncology therapeutic area positioning.

Broad incumbents

  • Bristol Myers Squibb (NLRP3 via IFM): Big pharma that had NLRP3 programs via the IFM Due (originally with BMS) and broader inflammation pipeline; comparable therapeutic area with vastly greater scale.
  • Novo Nordisk: Investor in NodThera and developer of semaglutide; overlapping cardiometabolic/obesity franchise where NodThera's anti-inflammatory approach could be complementary or competitive.
  • AstraZeneca: Major player in cardiometabolic disease with the Farxiga (dapagliflozin) franchise and an obesity franchise led by ex-NodThera board member Elisabeth Björk; overlapping therapeutic area and large commercial scale.
  • Amgen: Major inflammation and cardiometabolic player (Repatha, Otezla); comparable therapeutic area where NodThera's CMO Jyothis George previously led obesity medical affairs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

NodThera social profiles

Digital presence

NodThera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NodThera leadership team

Management profile

Number of profiles

Profiles12 records

NodThera funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NodThera M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NodThera

What does NodThera do?

NodThera is a clinical-stage biotechnology company developing a portfolio of brain-penetrant, oral small-molecule NLRP3 inflammasome inhibitors designed to treat chronic cardiometabolic and neuroinflammatory diseases. The company's pipeline includes three clinical-stage drug candidates: Ruvonoflast (NT-0796) as the lead molecule for cardiometabolic diseases currently in Phase 2 trials, NT-0150 as a next-generation brain-penetrant inhibitor for neuroinflammatory diseases in Phase 1, and NT-0249 as a CSF-penetrant Phase 2-ready candidate.

Is NodThera a public or private company?

NodThera is a private company. It is classified as venture growth investor backed and is currently operating.

When was NodThera founded?

NodThera was founded in 2016. It employs 11 to 50 people.

Where is NodThera based?

NodThera is headquartered in Little Chesterford, United Kingdom, in the Europe region.

Who are NodThera's main competitors?

Direct peers on record are Olatec Therapeutics, Inflazome (Roche) and IFM Tre (Novartis). Emerging players are Zydus Cadila (NLRP3 programs), Kymera Therapeutics and Bicycle Therapeutics. Broad incumbents are Bristol Myers Squibb (NLRP3 via IFM), Novo Nordisk, AstraZeneca and Amgen.

Does NodThera have an API?

No public API is recorded for NodThera.

What industry is NodThera in?

NodThera's product category is Inflammatory Disease Therapeutics. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterNodThera rebrands as Rezera, posts positive Phase II data ahead of PAD trialNodThera rebranded as Rezera and announced positive topline data from a Phase II study of its lead NLRP3 inhibitor, ruvonoflast. The company plans to advance the drug into a Phase III trial for peripheral artery disease in the first half of 2027. It also appointed Geoff McDonough as CEO and other executives.Neurology liveNodThera’s NT-0796 Shows Promise as Parkinson Disease Treatment in Phase 1b/2a TrialNodThera reported that its NLRP3 inflammasome inhibitor NT-0796 reduced inflammatory and disease-specific biomarkers in patients with Parkinson’s disease during a phase 1b/2a trial. The treatment demonstrated favorable safety, tolerability, and sustained anti-inflammatory effects over 28 days, supporting plans for ongoing phase 2 studies. These findings suggest NT-0796 may serve as a potential long-term, disease-modifying oral therapy for Parkinson’s.PharmExecStudy Finds Parkinson Disease Drug Nearly Matches Wegovy in Weight Loss EffectsNodThera published preclinical study results indicating that its investigational NLRP3 inhibitors, NT-0249 and NT-0796, achieved weight loss effects comparable to Wegovy in diet-induced obesity mouse models. The study also found that these compounds reduced inflammatory biomarkers associated with heart disease and may help prevent weight regain after discontinuation of GLP-1 therapies. These findings support the ongoing Phase IIa clinical trial of NodThera's brain-penetrant inhibitors for treating obesity.Daily Medical NewsNLRP3 inhibitor reduces inflammatory biomarkers in high-risk patientsNodThera reported that its NLRP3 inhibitor, ruvonoflast, significantly reduced high-sensitivity C-reactive protein and other inflammatory biomarkers compared to placebo in a phase 1b trial involving patients with high cardiovascular risk. The drug's efficacy profile supports the advancement of two larger phase 2 trials, RESOLVE-1 and RESOLVE-2, which are scheduled to report results in 2026.GlobeNewswireNodThera to Participate in April Investor ConferencesNodThera announced its participation in three investor conferences: Piper Sandler 3rd Annual Virtual Cardio Day on April 1, the 25th Annual Needham Virtual Healthcare Conference on April 13, and the Piper Sandler Spring Biopharma Symposium on April 15. The company, a clinical-stage NLRP3 inhibitor developer, will present at these virtual and in-person events.GlobeNewswireNodThera to Present at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceNodThera, a clinical-stage biotech company developing NLRP3 inhibitors for cardiometabolic and neuroinflammatory diseases, announced that CEO Geoff McDonough will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, in a virtual format. The presentation is scheduled for 11:20 AM ET. NodThera is headquartered in Boston with an R&D base in the UK.Endpoints NewsGeoff McDonough's big plans for NodThera's NLRP3; Enhertu leader steps down at DaiichiGeoff McDonough, the former CEO of Generation Bio, has joined NodThera to lead its development efforts regarding the NLRP3 target. The article also notes that the leader of Enhertu is stepping down at Daiichi Sankyo.GlobeNewswireNodThera Appoints Geoff McDonough, M.D., as Chief Executive OfficerNodThera appointed Geoff McDonough, M.D., as CEO ahead of Phase 2 trial readouts. The company plans to report results from RESOLVE-1 and RESOLVE-2 in mid-2026 and Q3 2026, with a Phase 3 trial starting in H1 2027.GlobeNewswireNodThera Announces Presentation at the 44th Annual J.P. Morgan Healthcare ConferenceNodThera announced that CFO Chris Guiffre will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, in San Francisco. The company, developing NLRP3 inhibitors for chronic inflammatory diseases, is backed by investors including 5AM Ventures and Blue Owl Capital.Neurology liveAnti-Inflammatory Effects of NT-0796 Warrant Future Studies in Parkinson Disease, NeurodegenerationA Phase 1b open-label study conducted by NodThera evaluated its NLRP3 inflammasome inhibitor NT-0796 in 4 healthy volunteers and 10 Parkinson disease patients, finding that the drug rapidly reduced systemic and central inflammatory markers including CSF IL-1β, CCL2, IL-6, and IL-8 to levels comparable to healthy controls over 28 days of treatment. Exploratory biomarkers showed that 5 of 8 participants experienced at least 10% decreases in neuroinflammatory and axonal injury markers (NfL and sTREM2), while pharmacokinetic data demonstrated robust CNS penetration with estimated brain concentrations exceeding the drug's IC50 values for both peripheral and central IL-1β inhibition. The study concluded that future blinded, placebo-controlled trials are needed, and NT-0796 is simultaneously being assessed in an ongoing Phase 2 obesity trial (RESOLVE-1) with data expected in Q2 2026.